OCV Partners
Venture capitalLos Angeles · Pre-Seed–Late Stage · 4 people tracked
Investment thesis
OCV Partners targets differentiated technology companies across two core focus areas: Technology (SaaS, FinTech, and PropTech) and Healthcare (Healthcare SaaS, Digital Health, MedTech, and BioTech). The firm leverages its founder background and operational expertise to support companies building disruptive platforms, particularly those enabling precision healthcare approaches, optimizing treatment decisions, removing access barriers, and accelerating new treatment discovery. The firm is flexible capital that can lead rounds but does not require to do so.
Source: firm website, verified Jul 21, 2026.
Team · 4 people
from the firm's websiteWhat they invest in
from 4 of 23 portfolio companiesMedical Devices ×2AI & Machine Learning ×1Biotech ×1Creator Economy ×1Cybersecurity ×1Developer Tools ×1Enterprise Software ×1Healthtech ×1
HQs:United States×1
Investments · 23 tracked
founders shown can be your intro pathDevelops novel oncology therapeutics using breakthrough medicinal chemistry technology and biomarker-driven assays to accelerate drug discovery and clinical approval timelines.
Fully integrated infant nutrition company translating nutrition science and breastmilk research into products.
Experience-first development company creating immersive spaces that foster imagination, connection, and creativity, including the Museum of Ice Cream.
Finch is a microbiome therapeutics company that develops innovative microbiome assets designed from human microbiota transplantation studies, targeting a range of therapeutic areas. The company holds a robust intellectual property portfolio in the microbiome field.
BiotechMedical Devices
Microbiome engineering company developing novel microbial therapies using machine-learning algorithms to address serious medical needs.
Subscription-based mobile app helping small business owners win jobs, track payments, and manage client payment options.
Data-driven legal technology platform providing an end-to-end solution combining technology, funding, and expertise to efficiently resolve civil cases.
Builds open source tools empowering developers to create trustful connected ecosystems.
Ockam is an open-source library that enables developers to build secure communication channels with end-to-end encryption and mutual authentication across any network, cloud, or on-premises infrastructure. The toolkit works at the application layer to establish private connections between systems without requiring infrastructure changes or exposing endpoints publicly.
CybersecurityDeveloper Tools
Social Native provides a platform for user-generated content (UGC) and influencer discovery that enables brands to access authentic social content across the consumer journey. The platform helps businesses build communities of brand ambassadors and influencers to scale their stories.
Creator EconomyMarketing TechSocial
David Shadpour(Founder & CEO)Eytan Elbaz(Co-Founder)
Therapeutic company focused on validated targets for treating neurological and psychiatric disorders.
Gene editing company using proprietary technology for cancer immunotherapy, gene therapy, and precision agriculture applications.
Rad AI develops generative AI models and automation solutions specifically designed for radiology and healthcare workflows. The platform helps physicians and health systems reduce radiologist burnout, save time, and improve patient care.
AI & Machine LearningEnterprise SoftwareHealthtechMedical Devices
Dr. Jeff Chang(Co-founder)Doktor Gurson(Co-founder)
Cybersecurity company providing automated breach and attack simulation solutions to enterprise customers.
Online platform enabling users to create customized branded content by connecting with relevant creators based on interests and brand affinity.
Online subscription fashion retailer carrying shoes, handbags, jewelry, and denim through brands including Fabletics, Justfab, ShoeDazzle, and Savage x Fenty.
Clinical-stage biotechnology company developing novel antibody-based therapies to transform cancer treatment.
Board seats · per SEC filings
what is this? ⓘ$95.5M raise · filed May 2026 · via Hemi B. Zucker, Hemi S. Zucker
Inferred from directors named on each company's SEC Form D — public regulatory data, not a portfolio list published by the firm.
Frequently asked questions
- What stage does OCV Partners invest at?
- OCV Partners invests at the Pre-Seed, Seed, Series A, Series B, Series C, Growth, Late Stage stages.
- What sectors does OCV Partners focus on?
- OCV Partners focuses on AI & Machine Learning, Biotech, Digital Health, Fintech, Medical Devices, PropTech, SaaS.
- Where is OCV Partners located?
- OCV Partners is headquartered in Los Angeles, US.
- Does OCV Partners lead rounds?
- Yes, OCV Partners leads investment rounds.
Similar investors
B Capital is a venture capital firm managing over $12 billion in assets with a stage-based fund approach. The firm invests across early to late-stage companies in technology, healthcare, and energy & resilience sectors, with 200+ portfolio companies and 9 global offices.
DCVC is a deep tech venture capital firm with over a dozen years of experience backing entrepreneurs using computational approaches to solve trillion-dollar problems across industries including AI, climate, materials science, robotics, space, and biology.
A globally recognized venture capital firm designed to provide access to highly competitive venture deals to individual investors, consistently recognized for top-decile DPI performance and as one of the most active US venture firms.
GV is Alphabet's venture capital arm, established in 2009 as Google Ventures. Operating with long time horizons and over $13 billion in assets under management, the firm invests across technology and life sciences sectors from seed to growth stages, supporting 400 active portfolio companies across North America, Europe, and Israel.
Khosla Ventures is a technology-focused investment firm that seeks companies leveraging disruptive technological advances to solve large-scale problems across multiple industries. The firm emphasizes proprietary technology, business model innovation, and early-stage, bold investments with unfair advantages.